Skip to main content

Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 24, 2024.

via HealthDay

THURSDAY, Oct. 24, 2024 -- For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed electric fields to induce natural cell death through an apoptosis-like process, is feasible and safe and can prevent the need for insulin therapy when combined with semaglutide, according to a study presented at UEG Week, the annual meeting of United European Gastroenterology, held from Oct. 4 to 7 in Vienna.

Celine Busch, M.D., from Amsterdam University Medical Center, and colleagues presented 24-month results from a single-arm, single-center, first-in-human study conducted in 14 patients with T2D. All patients underwent the ReCET procedure, followed by a two-week isocaloric liquid diet; semaglutide was titrated up to 1 mg/week thereafter.

The researchers found that the technical success rate of the ReCET procedure was 100 percent; the median axial treatment length was 12 cm, and median procedure time was 58 minutes. There were no serious adverse events related to the device or severe hypoglycemic events. Thirteen of the patients (93 percent) tolerated the maximum dose of semaglutide. Twelve patients (86 percent) were still not using insulin at six and 12 months, but they had significant improvements in glycemic control and metabolic parameters. All 11 patients who completed the 24-month follow-up remained off insulin with adequate glycemic control.

"These findings are very encouraging, suggesting that ReCET is a safe and feasible procedure that, when combined with semaglutide, can effectively eliminate the need for insulin therapy," Busch said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Muscle Ultrasound Can Detect Insulin Resistance

MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound...

Disparities Seen in Continuous Glucose Monitor Rx by Language Preference

FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...

ADA: Insulin Efsitora Noninferior to Glargine for Reducing HbA1c in Adults With Type 2 Diabetes

FRIDAY, June 27, 2025 -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.